The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma
Open Access
- 3 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in American Journal of Clinical Dermatology
- Vol. 22 (3), 407-414
- https://doi.org/10.1007/s40257-021-00591-x
Abstract
Background Chlormethine/mechlorethamine gel is a skin-directed therapy for patients with mycosis fungoides cutaneous T-cell lymphoma. Currently, real-world data on chlormethine gel are lacking. Objective Our objective was to analyze the effect of chlormethine gel in combination with other therapies on efficacy, safety, and health-related quality of life in a real-world setting. Methods This prospective, observational study enrolled adult patients actively using chlormethine gel. Patients were monitored for up to 2 years during standard-of-care clinic visits. No specific visit schedules or clinical assessments, with the exception of patient-completed questionnaires, were mandated because of the expected variability in practice patterns. The primary efficacy endpoint was the proportion of patients with stage IA–IB disease receiving chlormethine + topical corticosteroids + other with ≥ 50% decrease in body surface area from baseline to 12 months. Response was assessed at each visit using by-time analysis, which investigates the trend to treatment response and allows assessment of response over time. Health-related quality of life was assessed with the Skindex-29 questionnaire. Results In total, 298 patients were monitored. At 12 months post-treatment initiation, 44.4% (chlormethine + topical corticosteroids + other) and 45.1% (patients receiving chlormethine + other treatment) of efficacy-evaluable patients were responders. By-time analysis demonstrated that peak response occurred (chlormethine + other; 66.7%) at 18 months. There was a significant correlation between responder status and lower post-baseline Skindex-29 scores. Conclusions This real-world study confirmed that chlormethine gel is an important therapeutic option for patients with mycosis fungoides and contributes to reducing the severity of skin lesions and improving health-related quality of life.Keywords
Funding Information
- Helsinn Therapeutics
This publication has 17 references indexed in Scilit:
- Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Cutaneous T‐cell lymphoma: 2017 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2017
- European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017European Journal of Cancer, 2017
- Topical Chemotherapy in Cutaneous T-cell LymphomaJAMA Dermatology, 2013
- Interpretation of Skindex-29 Scores: Cutoffs for Mild, Moderate, and Severe Impairment of Health-Related Quality of LifeJournal of Investigative Dermatology, 2011
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005
- Topical Nitrogen Mustard in the Management of Mycosis FungoidesArchives of Dermatology, 2003
- Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients With Skin DiseasesArchives of Dermatology, 1997
- Topical Treatment of Early Cutaneous T-cell LymphomaHematology/Oncology Clinics of North America, 1995
- Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphomaJournal of the American Academy of Dermatology, 1989